Clinical

Videos

Data presented at SUO indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.

Ramaprasad Srinivasan, MD, PhD, on the Design of the Study of MK-6482 in VHL-Associated Disease

The kidney cancer expert from the National Cancer Institute spoke about what ongoing research in the field of kidney cancer is most encouraging and where research should continue to be focused.

Ramaprasad Srinivasan, MD, PhD, on Upcoming Research for Kidney Cancer

Articles

Researchers identified the prevalence of germline mutations associated with the early-onset renal cell carcinoma, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.

Study Identifies Prevalence of Germline Mutations Associated with RCC

A phase 2 study found that the investigational HIF-2α inhibitor MK-6482 has durable efficacy in patients with Von Hippel-Lindau associated clear cell renal cell carcinoma and non-renal lesions.

MK-6482 Demonstrates Durable Efficacy For VHL-Associated Clear Cell RCC

The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

HIF-2α Inhibition Warranted for VHL-Associated Clear Cell Renal Cell Carcinoma

Researchers demonstrated for the first time that radiation remodels T-cell responses found within the tumors of patients with renal cell carcinoma.

Study Finds Radiation Remodels T-Cell Responses in Patients with RCC

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

BIONIKK Trial Sees Improved Responses with Molecularly-Guided Therapy in Patients with mRCC

With a follow-up of 4 years, nivolumab plus ipilimumab continued to demonstrate superior, long-term overall survival and durable responses compared to sunitinib in patients with advanced renal cell carcinoma.

4-Year Results from Phase 3 CheckMate-214 Trial Continue to Show Long-Term Benefit in RCC

In a webinar, a multidisciplinary team from Duke Cancer Center came together to discuss the differences in treating patients with genitourinary cancer as a result of the COVID-19 pandemic.

Alterations in Genitourinary Cancer Care Due to COVID-19

A recent study examined pancreatic metastases to understand why patients with this particular kidney cancer have better prognoses, and sought to characterize the clinical behavior, therapeutic implications, and underlying biology of this type of cancer.

Kidney Cancer | Topics